Regenerative medicine ATMPs for T1D

Optimising the manufacturing of ATMPs towards clinical trials especially for T1D: BIOT have been coordinating H2020 ATMP-developing projects and strongly interested in scaling up such products for clinical applications. We are interested in pancreatic organoid printing, providing hiPSC-derived pancreatic cells for the treatment of Type 1 diabetes and a portfolio of patents for bioartificial pancreas device, potentially coordinating a consortium for this purpose. Furthermore, as potential partners we are experienced in providing cardiac cells and spheriods and neuronal and glia cells and spheroids for bioprinting partners and for ATMP product development. We are also involved in ASO therapy development, providing preclinical human in vitro testing methods for ultra-rare diseases and experienced in genetic engineering of human stem cell lines.